Rare cancers, which affect over 1.8 million patients globally, often present diagnostic challenges due to their low prevalence and tricky tumor locations. Traditional tissue biopsies can be risky or impossible for tumors in sensitive areas (e.g., brainstem, pancreas) or those that are small and diffuse. Liquid biopsies, with their non-invasive nature and ability to detect circulating biomarkers, are emerging as a lifeline for these patients, offering safer, more accessible diagnosis. This article explores how liquid biopsies are transforming rare cancer care and their growing role in niche oncology markets.

Rare cancers, defined as having fewer than 6 cases per 100,000 people annually, include conditions like mesothelioma, angiosarcoma, and certain pediatric tumors. For these patients, every diagnostic step is critical—delayed or inaccurate diagnosis can drastically reduce survival chances. Liquid biopsies bypass the need for invasive procedures, making sampling feasible even for patients with fragile health or tumors inaccessible to biopsy needles. For example, in mesothelioma, a rare lung cancer linked to asbestos exposure, liquid biopsies detect specific mutations (e.g., BAP1) with 70% sensitivity, avoiding the risks of thoracic tissue biopsies. Similarly, pediatric patients with central nervous system (CNS) tumors benefit from avoiding brain biopsies, reducing trauma and infection risks.

The liquid biopsy market’s focus on rare cancers is expanding. Companies like GRAIL and Guardant Health have developed panels targeting rare mutations, while startups like Tempus and Flatiron Health aggregate real-world data to improve test accuracy for uncommon tumor types. In Europe, the EU’s Orphan Drug Regulation incentivizes R&D for rare diseases, encouraging firms to invest in rare cancer liquid biopsy tests. These efforts have not only improved diagnosis rates but also facilitated access to clinical trials, as liquid biopsies provide consistent biomarker data for trial eligibility. To assess the size of the rare cancer liquid biopsy market, leading players, and growth projections, the Liquid Biopsy Market rare cancer applications report by Market Research Future offers comprehensive analysis, including case studies and regional adoption trends.

Despite progress, challenges remain. Rare cancers have diverse genetic profiles, making it hard to develop universal panels. Many mutations are unique to individual patients, requiring customized testing. Additionally, limited patient data for rare cancers complicates validation of liquid biopsy accuracy. However, global initiatives like the International Rare Cancers Initiative (IRCI) are collecting genomic data from rare cancer patients, accelerating test development. As liquid biopsies become more tailored to rare tumors, they will not only improve diagnosis but also support the development of targeted therapies, giving hope to patients who’ve long been underserved by oncology advancements.